Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 8/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 6/20 | 0.76 |
| ▸ | MAPT | P10636 | 4/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | MIF | P14174 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9973669 | 1.00 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1SMN1; SMN2TP53 | |
| SCHEMBL14197006 | 1.00 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1SMN1; SMN2TP53 | |
| SCHEMBL20639350 | 1.00 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1SMN1; SMN2TP53 | |
| SCHEMBL17616912 | 1.00 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1SMN1; SMN2TP53 | |
| SCHEMBL598727 | 1.00 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1SMN1; SMN2TP53 | |
| SCHEMBL9973671 | 0.92 | CYP3A4 (0.85) | CYP3A4SLCO1B3SLCO1B1SMN1; SMN2TP53 | |
| SCHEMBL10019477 | 0.87 | CYP3A4 (0.77) | CYP3A4SLCO1B3SLCO1B1SMN1; SMN2TP53 | |
| SCHEMBL9973651 | 0.87 | CYP3A4 (0.77) | CYP3A4SLCO1B3SLCO1B1SMN1; SMN2TP53 | |
| Azadiradione SCHEMBL19588462 | 0.87 | CYP3A4 (0.77) | CYP3A4SLCO1B3SLCO1B1SMN1; SMN2TP53 | |
| Azadiradione SCHEMBL29398035 | 0.87 | CYP3A4 (0.77) | CYP3A4SLCO1B3SLCO1B1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289412-B2 | Role of limonoid compounds as neuroprotective agents | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289412-B2 | Role of limonoid compounds as neuroprotective agents | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-03-22 | — | — | US | disclosed |
| US-8114619-B2 | Methods for diagnosis and optimizing treatment of multiple sclerosis | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114619-B2 | Methods for diagnosis and optimizing treatment of multiple sclerosis | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100137420-A1 | Methods and Compositions for Diagnosis and Treatment of Multiple Sclerosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-03 | — | — | US | disclosed |
| US-20100137420-A1 | Methods and Compositions for Diagnosis and Treatment of Multiple Sclerosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-03 | — | — | US | disclosed |
| US-20100056617-A1 | Role of limonoid compounds as neuroprotective agents | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056617-A1 | Role of limonoid compounds as neuroprotective agents | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056617-A1 | Role of limonoid compounds as neuroprotective agents | NLN, SMN1; SMN2, CLN6 | CYP3A4 4706/4885SLCO1B3 4501/4885SLCO1B1 4617/4885 |
| US-20100137420-A1 | Methods and Compositions for Diagnosis and Treatment of Multiple Sclerosis | CTSB, CSTB, CTSG | CYP3A4 4717/4885SLCO1B3 3124/4885SLCO1B1 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.